Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    TCM soup can help cut COVID-19 death rate of patients in half, study shows

    By WANG XIAOYU | CHINA DAILY | Updated: 2021-05-10 09:21
    Share
    Share - WeChat
    Pharmacists dispense medicines according to Qingfei Paidu Soup prescriptions at Anhui University of Chinese Medicine on Feb 21, 2020. [Photo/Xinhua]

    Qingfei paidu soup, a widely used traditional Chinese medicine to treat COVID-19 infections, can help reduce the rate of death among hospitalized patients by half, a recent study has shown.

    The study examines more than 8,900 COVID-19 cases that received treatment at 15 hospitals in Hubei province-the hardest-hit region during the epidemic-from January to May last year, with nearly 30 percent of them having taken qingfei paidu as part of their therapies.

    Results suggest that the mortality rate for those undergoing the TCM treatment stands at 1.2 percent, while the rate for other patients is 4.8 percent.

    The study, led by researchers from Fuwai Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College, concluded that the use of qingfei paidu is associated with a 50 percent reduction of mortality in hospitalized COVID-19 patients, without amplifying the risk of developing acute liver or kidney injuries.

    It was first published on preprint website MedRxiv.org in late December. On March 31, it was released on Phytomedicine, a peer-reviewed journal.

    Li Jing, head of the research team, said based on the national diagnosis and treatment guideline for COVID-19 diseases, qingfei paidu is the only prescription that is recommended for treating all patients ranging from mild to critical cases.

    "The extensive delivery of TCM medication in hospitalized patients during the outbreak had created a sound base for our research because when appraising clinical effectiveness of a certain drug, it is crucial to start by collecting and analyzing from a large enough number of cases," she said.

    Qingfei paidu is a concoction that includes dozens of TCM herbs and roots, including ephedra, licorice root and bitter almond. The initial version of the prescription is believed to have originated during the Eastern Han Dynasty (25-220).

    Zhang Boli, president of the Tianjin University of Traditional Chinese Medicine, said during an earlier interview that preliminary studies show the therapy mainly works on lungs while offering protection for some other organs against the virus. It can also stem the virus's replication, Zhang said.

    According to the National Administration of Traditional Chinese Medicine, previous studies have already attested to the herbal prescription's efficacy in preventing mild and moderate cases from worsening into severe infections, but evidence of its role in lowering the death rate was lacking.

    "The study is by far the largest clinical research on qingfei paidu and its findings have provided potent evidence for proving its marked efficacy in saving the lives of COVID-19 patients," the administration said.

    As of now, there is no approved specific treatment for COVID-19 patients. During the fight against the epidemic, 92 percent of confirmed patients had undergone TCM therapies, with the efficacy rate in Hubei reaching 90 percent, according to a white paper released in June.

    Li said the new study is retrospective and based on real-world cases.

    "If a randomized, double-blind, placebo-controlled clinical study can be conducted in the future, the TCM drug's clinical efficacy can be further verified, and its global application is expected to expand," she added.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    人妻少妇看A偷人无码精品视频| 中文字幕日韩在线| 人妻精品久久久久中文字幕| 久久亚洲精品无码AV红樱桃| 人妻少妇看A偷人无码电影 | 一本色道久久HEZYO无码| 亚洲电影中文字幕| 人妻无码人妻有码中文字幕| 国产AV一区二区三区无码野战| 特级做A爰片毛片免费看无码| 中文在线√天堂| 一本大道久久东京热无码AV| 精品欧洲av无码一区二区| 精品无码国产自产在线观看水浒传 | 99久久国产热无码精品免费| 亚洲精品无码午夜福利中文字幕| 中文字幕在线资源| 亚洲日韩v无码中文字幕| 国产日韩AV免费无码一区二区三区 | 亚洲中文字幕无码爆乳av中文| 无码人妻精品一区二区三区66| 日本无码色情三级播放| 最新中文字幕在线| 人妻少妇精品视中文字幕国语| 日本妇人成熟免费中文字幕| 亚洲gv天堂无码男同在线观看| 免费无码国产V片在线观看| 无码内射中文字幕岛国片| 性无码一区二区三区在线观看| 亚洲精品无码Av人在线观看国产| 精品无码成人片一区二区98| 亚洲午夜国产精品无码老牛影视 | 亚洲AV无码一区东京热久久| 成年无码av片完整版| 亚洲热妇无码AV在线播放| 亚洲VA中文字幕不卡无码| 亚洲国产精品无码久久久秋霞2| 亚洲国产精品成人精品无码区| 亚洲av中文无码乱人伦在线r▽| 亚洲AV无码专区亚洲AV伊甸园| 无码人妻精品一区二区三区99仓本 |